Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-6

NZT, @ThePig is right, CHM hasn't dosed patient 5 yet and the 5 manufactured doses mean just 5, not additionally ones to the 4.

IMU is facing similar problems with recruiting and placing the patients into the participating hospitals / institutes. Just 18 months ago IMU hoped to complete its rego trial for Azer-Cel by end'25 / early '26, now blown out to '28/'29.

It all takes more time and sometimes, like at IMU, they have to re-design the trial and to start again with an improved drug-combo.

Like at IMU, they got assets that one day could become a winner but without funding it will be a huge uphill battle. Big Pharma support is needed and that, unfortunately, is nowhere to be seen.

GLTA